VivoSeq
Other

Symptomatic Irreversible Pulpitis

4

Pipeline Programs

3

Active Trials

4

Companies Involved

Symptomatic Irreversible Pulpitis is an early-stage landscape with 4 programs across 4 companies. The most active players are Shanghai Argo Biopharmaceutical Co., Ltd., Bayer, Eli Lilly. 1 therapy is approved.

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

19/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

7

clinical trials

Completed4 · 57%
Not yet recruiting2 · 29%
Recruiting1 · 14%

Trial Activity

7 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)